Mirum Pharmaceuticals, Inc. (MIRM)
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals NASDAQ: MIRM said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
Mirum Pharmaceuticals NASDAQ: MIRM reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events
Mirum Pharmaceuticals is approaching major catalysts, notably the FDA's PDUFA decision for zilurgisertib (Sept. 26) & pivotal Phase 3 data on its chronic hepatitis D drug, a potential blockbuster. MIRM's pipeline expansion and strategic acquisitions have delayed profitability to 2028, but management raised FY 2026 sales guidance to $680–$700 million. Strong commercial traction from LIVMARLI and bile acid products drove Q2 revenue above expectations, but operating losses widened due to R&D and integration costs.
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals Q2 Earnings Call Highlights
Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.12 per share a year ago.
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.
